Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor α signaling

Toxicology in Vitro

Volumn 24, Issue 1, 2010, Pages 154-159

  Zhao, Yan ^a   Okuyama, Manabu ^b   Hashimoto, Hiroyuki ^b   Tagawa, Yoshiaki ^b   Jomori, Takahito ^b   Yang, Baofeng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

Author keywords

Fibrates; Myotoxicity; Peroxisome proliferator activated receptor ; Statins

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ATORVASTATIN; BEZAFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN KINASE B; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATE DEHYDROGENASE KINASE 4;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; RHABDOMYOLYSIS; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

ANTILIPEMIC AGENTS; APOPTOSIS; BEZAFIBRATE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HUMANS; IMMUNOPRECIPITATION; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PPAR ALPHA; PROTEIN KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA, MESSENGER;

EID: 72049084255     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.08.001     Document Type: Article

References (41)

1. Alsheikh-Ali A.A., Kuvin J.T., and Karas R.H. Risk of adverse events with fibrates. American Journal of Cardiology 94 (2004) 935-938
2. Arora R., Liebo M., and Maldonado F. Statin-induced myopathy: the two faces of Janus. Journal of Cardiovascular Pharmacology and Therapeutics 11 (2006) 105-112
3. Baer A.N., and Wortmann R.L. Myotoxicity associated with lipid-lowering drugs. Current Opinion in Rheumatology 19 (2007) 67-73
4. Bloomgarden Z.T. Insulin resistance, dyslipidemia, and cardiovascular disease. Diabetes Care 30 (2007) 2164-2170
5. Brunzell J.D., and Ayyobi A.F. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. American Journal of Medicine 115 (2003) 24S-28S
6. Cortellaro M., Cofrancesco E., Boschetti C., Cortellaro F., Mancini M., Mariani M., and Paoletti R. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin alone and in combination treatment. Thrombosis and Haemostasis 83 (2000) 549-553
7. De Souza A.T., Cornwell P.D., Dai X., Caguyong M.J., and Ulrich R.G. Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle. Toxicology Science 92 (2006) 578-586
8. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 20 (1999) 649-688
9. Du J., Wang X., Miereles C., Bailey J.L., Debigare R., Zheng B., Price S.R., and Mitch W.E. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. Journal of Clinical Investigation 113 (2004) 115-123
10. Franke T.F., Hornik C.P., Segev L., Shostak G.A., and Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 22 (2003) 8983-8998
11. Frost R.A., and Lang C.H. Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. Journal of Applied Physiology 103 (2007) 378-387
12. Gavish D., Leibovitz E., Shapira I., and Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. Journal of Internal Medicine 247 (2000) 563-569
13. Ginsberg H.N., Zhang Y.L., and Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity 14 (2006) 41S-49S
14. Graham D.J., Staffa J.A., Shatin D., Andrade S.E., Schech S.D., La Grenade L., Gurwitz J.H., Chan K.A., Goodman M.J., and Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. Journal of the American Medical Association 292 (2004) 2585-2590
15. Holness M.J., and Sugden M.C. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochemical Society Transactions 31 (2003) 1143-1151
16. Johnson T.E., Zhang X., Shi S., and Umbenhauer D.R. Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. Toxicology and Applied Pharmacology 208 (2005) 210-221
17. Kubota T., Yano T., Fujisaki K., Itoh Y., and Oishi R. Fenofibrate induces apoptotic injury in cultured human hepatocytes by inhibiting phosphorylation of Akt. Apoptosis 10 (2005) 349-358
18. Maiguma T., Fujisaki K., Itoh Y., Makino K., Teshima D., Takahashi-Yanaga F., Sasaguri T., and Oishi R. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. Naunyn. Schmiedebergs. Archives of Pharmacology 367 (2003) 289-296
19. Marte B.M., and Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends in Biochemical Sciences 22 (1997) 355-358
20. Matzno S., Tazuya-Murayama K., Tanaka H., Yasuda S., Mishima M., Uchida T., Nakabayashi T., and Matsuyama K. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. Journal of Pharmacy and Pharmacology 55 (2003) 795-802
21. 2+-dependent caspase-12 activation. Life Science 78 (2006) 1892-1899
22. Menuet R., Lavie C.J., and Milani R.V. Importance and management of dyslipidemia in the metabolic syndrome. American Journal of The Medical Sciences 330 (2005) 295-302
23. Motojima K. A metabolic switching hypothesis for the first step in the hypolipidemic effects of fibrates. Biological and Pharmaceutical Bulletin 25 (2002) 1509-1511
24. Motojima K., and Seto K. Fibrates and statins rapidly and synergistically induce pyruvate dehydrogenase kinase 4 mRNA in the liver and muscles of mice. Biological and Pharmaceutical Bulletin 26 (2003) 954-958
25. Owczarek J., Jasińska M., and Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacological Reports 57 (2005) 23-34
26. Pauciullo P., Borgnino C., Paoletti R., Mariani M., and Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 150 (2000) 429-436
27. Ruotolo G., and Howard B.V. Dyslipidemia of the metabolic syndrome. Current Cardiology Reports 4 (2002) 494-500
28. Sharobeem K.M., Madden B.P., Millner R., Rolfe L.M., Seymour C.A., and Parker J. Acute renal failure after cardiopulmonary bypass: a possible association with drugs of the fibrate group. Journal of Cardiovascular Pharmacology and Therapeutics 5 (2000) 33-39
29. Southgate R.J., Bruce C.R., Carey A.L., Steinberg G.R., Walder K., Monks R., Watt M.J., Hawley J.A., Birnbaum M.J., and Febbraio M.A. PGC-1alpha gene expression is down-regulated by Akt-mediated phosphorylation and nuclear exclusion of FoxO1 in insulin-stimulated skeletal muscle. FASEB Journal 19 (2005) 2072-2074
30. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
31. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
32. Sugden M.C., and Holness M.J. Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases. Archives of Physiology and Biochemistry 112 (2006) 139-149
33. Sugden M.C., Bulmer K., and Holness M.J. Fuel-sensing mechanisms integrating lipid and carbohydrate utilization. Biochemical Society Transactions 29 (2001) 272-278
34. Sun Y., Zhang L., Gu H.F., Han W., Ren M., Wang F., Gong B., Wang L., Guo H., Xin W., Zhao J., and Gao L. Peroxisome proliferator-activated receptor-alpha regulates the expression of pancreatic/duodenal homeobox-1 in rat insulinoma (INS-1) cells and ameliorates glucose-induced insulin secretion impaired by palmitate. Endocrinology 149 (2008) 662-671
35. Tenenbaum A., and Fisman E.Z. Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?. Cardiovascular Diabetology 3 (2004) 10-13
36. Tenenbaum A., Motro M., and Fisman E.Z. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovascular Diabetology 4 (2005) 14-18
37. Tenenbaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., and Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Archives of Internal Medicine 165 (2005) 1154-1160
38. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
39. Workeneh B.T., Rondon-Berrios H., Zhang L., Hu Z., Ayehu G., Ferrando A., Kopple J.D., Wang H., Storer T., Fournier M., Lee S.W., Du J., and Mitch W.E. Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions. Journal of the American Society of Nephrology 17 (2006) 3233-3239
40. Wu P., Peters J.M., and Harris R.A. Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha. Biochemical and Biophysical Research Communications 287 (2001) 391-396
41. Yang K.C., Fang C.C., Su T.C., and Lee Y.T. Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD. American Journal of Kidney Diseases 45 (2005) 57-60